[开放获取]   老年特应性皮炎诊疗专家共识（2023版）

doi:10.35541/cjd.20230427

Abstract

Abstract: 【Abstract】 Atopic dermatitis in the elderly （> 60 years old） differs from that in children and adults in terms of demographical characteristics, pathogenesis, clinical manifestations and complications, and special considerations are needed for its diagnosis and treatment. Thus, the Immunology Group of the Chinese Society of Dermatology developed an expert consensus on the diagnosis and treatment of atopic dermatitis in the elderly, aiming to standardize and guide the effective management of elderly patients with atopic dermatitis.

Key words: Dermatitis, atopic, Elderly, Diagnosis, Therapeutics, Consensus

Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of atopic dermatitis in the elderly （2023）[J]. Chinese Journal of Dermatology, 2023, 56(11): 991-999.doi:10.35541/cjd.20230427

References ［81］

［1］	中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
［2］	李巍, 王上上, 刘玉峰. 老年特应性皮炎: 一个新的临床亚型［J］. 中华皮肤科杂志, 2020,53（8）:654⁃657. doi: 10.35541/cjd.20190760.
［3］	Muto T, Hsieh SD, Sakurai Y, et al. Prevalence of atopic dermatitis in Japanese adults［J］. Br J Dermatol, 2003,148（1）:117⁃121. doi: 10.1046/j.1365⁃2133.2003.05092.x.
［4］	Saeki H, Tsunemi Y, Fujita H, et al. Prevalence of atopic dermatitis determined by clinical examination in Japanese adults［J］. J Dermatol, 2006,33（11）:817⁃819. doi: 10.1111/j.1346⁃8138.2006.00187.x.
［5］	Bozek A, Fisher A, Filipowska B, et al. Clinical features and immunological markers of atopic dermatitis in elderly patients［J］. Int Arch Allergy Immunol, 2012,157（4）:372⁃378. doi: 10. 1159/000329150.
［6］	Sybilski AJ, Raciborski F, Lipiec A, et al. Epidemiology of atopic dermatitis in Poland according to the Epidemiology of Allergic Disorders in Poland （ECAP） study［J］. J Dermatol, 2015,42（2）:140⁃147. doi: 10.1111/1346⁃8138.12731.
［7］	Salava A, Rieppo R, Lauerma A, et al. Age⁃dependent distribution of atopic dermatitis in primary care: a nationwide population⁃based study from Finland［J］. Acta Derm Venereol, 2022,102:adv00738. doi: 10.2340/actadv.v102.2287.
［8］	Laughter MR, Maymone M, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990⁃2017［J］. Br J Dermatol, 2021,184（2）:304⁃309. doi: 10.1111/bjd.19580.
［9］	Tanei R, Katsuoka K. Clinical analyses of atopic dermatitis in the aged［J］. J Dermatol, 2008,35（9）:562⁃569. doi: 10.1111/j.1346⁃8138.2008.00524.x.
［10］	Wang S, Zhu R, Gu C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China［J］. J Eur Acad Dermatol Venereol, 2020,34（10）:2346⁃2352. doi: 10.1111/ jdv.16346.
［11］	Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology［J］. Geriatr Gerontol Int, 2016,16 Suppl 1:75⁃86. doi: 10.1111/ggi.12771.
［12］	Tanei R. Atopic dermatitis in the elderly［J］. Inflamm Allergy Drug Targets, 2009,8（5）:398⁃404. doi: 10.2174/187152811090 8050398.
［13］	Williamson S, Merritt J, De Benedetto A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks［J］. Br J Dermatol, 2020,182（1）:47⁃54. doi: 10.1111/bjd.17896.
［14］	Birch J, Gil J. Senescence and the SASP: many therapeutic avenues［J］. Genes Dev, 2020,34（23⁃24）:1565⁃1576. doi: 10. 1101/gad.343129.120.
［15］	Zhou L, Leonard A, Pavel AB, et al. Age⁃specific changes in the molecular phenotype of patients with moderate⁃to⁃severe atopic dermatitis［J］. J Allergy Clin Immunol, 2019,144（1）:144⁃156. doi: 10.1016/j.jaci.2019.01.015.
［16］	Choi EH. Aging of the skin barrier［J］. Clin Dermatol, 2019,37（4）:336⁃345. doi: 10.1016/j.clindermatol.2019.04.009.
［17］	Kottner J, Lichterfeld A, Blume⁃Peytavi U. Transepidermal water loss in young and aged healthy humans: a systematic review and meta⁃analysis［J］. Arch Dermatol Res, 2013,305（4）:315⁃323. doi: 10.1007/s00403⁃012⁃1313⁃6.
［18］	Wlaschek M, Maity P, Makrantonaki E, et al. Connective tissue and fibroblast senescence in skin aging［J］. J Invest Dermatol, 2021,141（4S）:985⁃992. doi: 10.1016/j.jid.2020.11.010.
［19］	Lipozencić J, Wolf R. Atopic dermatitis: an update and review of the literature［J］. Dermatol Clin, 2007,25（4）:605⁃612, x. doi: 10.1016/j.det.2007.06.009.
［20］	Li F, Xie W, Chen Z, et al. Neuropeptide Y and receptors are associated with the pyroptosis of nucleus pulposus in aging and degenerative intervertebral discs of rats［J］. Neuropeptides, 2022,96:102284. doi: 10.1016/j.npep.2022.102284.
［21］	Langan SM, Irvine AD, Weidinger S. Atopic dermatitis［J］. Lancet, 2020,396（10247）:345⁃360. doi: 10.1016/S0140⁃6736（20）31286⁃1.
［22］	Bolognia JL, Schaffer JV, Cerroni L. Dermatology［M］. 4th ed. New York: Elsevier, 2018.
［23］	Bieber T, D′Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go?［J］. J Allergy Clin Immunol, 2017,139（4S）:S58⁃S64. doi: 10.1016/j.jaci.2017.01.008.
［24］	Yang L, Fu J, Zhou Y. Research progress in atopic march［J］. Front Immunol, 2020,11:1907. doi: 10.3389/fimmu.2020.01907.
［25］	Renert⁃Yuval Y, Del Duca E, Pavel AB, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults［J］. J Allergy Clin Immunol, 2021,148（1）:148⁃163. doi: 10.1016/j.jaci.2021.01.001.
［26］	Brunner PM, Israel A, Zhang N, et al. Early⁃onset pediatric atopic dermatitis is characterized by T（H）2/T（H）17/T（H）22⁃centered inflammation and lipid alterations［J］. J Allergy Clin Immunol, 2018,141（6）:2094⁃2106. doi: 10.1016/j.jaci.2018.02. 040.
［27］	Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis［J］. Clin Dermatol, 2018,36（5）:595⁃605. doi: 10.1016/j.clindermatol. 2018.05.007.
［28］	Yousaf M, Ayasse M, Ahmed A, et al. Association between atopic dermatitis and hypertension: a systematic review and meta⁃analysis［J］. Br J Dermatol, 2022,186（2）:227⁃235. doi: 10.1111/bjd.20661.
［29］	Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults［J］. Ann Allergy Asthma Immunol, 2018,121（5）:604⁃612.e3. doi: 10.1016/j.anai.2018.07.042.
［30］	Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders［J］. Am J Clin Dermatol, 2018,19（6）:821⁃838. doi: 10.1007/s40257⁃018⁃0383⁃4.
［31］	He H, Li R, Choi S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2020,124（1）:70⁃78. doi: 10.1016/j.anai.2019.10.013.
［32］	Brunner PM, Guttman⁃Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad⁃spectrum and targeted therapies［J］. J Allergy Clin Immunol, 2017,139（4S）:S65⁃S76. doi: 10.1016/j.jaci.2017.01.011.
［33］	Ahn C, Huang W. Clinical presentation of atopic dermatitis［J］. Adv Exp Med Biol, 2017,1027:39⁃46. doi: 10.1007/978⁃3⁃319⁃64804⁃0_4.
［34］	中华医学会皮肤性病学分会免疫学组, 中国医师协会皮肤科医师分会指南制定与规范委员会. 皮炎湿疹类疾病规范化诊断术语专家共识［J］. 中华皮肤科杂志, 2021,54（11）:937⁃942. doi: 10.35541/cjd.20210578.
［35］	宋志强, 邓思思. 对老年特应性皮炎的再认识［J］. 中华医学杂志, 2023,103（32）:2470⁃2474. doi: 10.3760/cma.j.cn112137⁃20221227⁃02706.
［36］	Yue W, Cheng D, Sun Z, et al. Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting⁃based study［J］. Br J Dermatol, 2023,188（3）:420⁃426. doi: 10.1093/bjd/ljac097.
［37］	Chello C, Carnicelli G, Sernicola A, et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature［J］. Int J Dermatol, 2020,59（6）:716⁃721. doi: 10.1111/ijd.14891.
［38］	姚煦.常用特应性皮炎严重度评估方法［J］. 中华皮肤科杂志, 2021,54（6）:539⁃541. doi: 10.35541/cjd.20200825.
［39］	中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识［J］. 中华皮肤科杂志, 2023,56（1）:5⁃15. doi: 10.35541/cjd.20220618.
［40］	Tanei R. Atopic dermatitis in older adults: a review of treatment options［J］. Drugs Aging, 2020,37（3）:149⁃160. doi: 10.1007/s40266⁃020⁃00750⁃5.
［41］	赵作涛, 高兴华. 中重度特应性皮炎系统药物达标治疗专家指导建议［J］. 中国皮肤性病学杂志, 2022,36（8）:855⁃864. doi: 10.13735/j.cjdv.1001⁃7089.202205115.
［42］	Teplitsky V, Mumcuoglu KY, Babai I, et al. House dust mites on skin, clothes, and bedding of atopic dermatitis patients［J］. Int J Dermatol, 2008,47（8）:790⁃795. doi: 10.1111/j.1365⁃4632.2008. 03657.x.
［43］	Katoh N, Ohya Y, Ikeda M, et al. Japanese guidelines for atopic dermatitis 2020［J］. Allergol Int, 2020,69（3）:356⁃369. doi: 10. 1016/j.alit.2020.02.006.
［44］	Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema ⁃ part II: non⁃systemic treatments and treatment recommendations for special AE patient populations［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:1904⁃1926. doi: 10.1111/jdv.18429.
［45］	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组, 中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识［J］. 中华皮肤科杂志, 2022,55（4）:281⁃288. doi: 10.35541/cjd.20210833.
［46］	Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema［J］. Health Technol Assess, 2000,4（37）:1⁃191.
［47］	Fishbein AB, Silverberg JI, Wilson EJ, et al. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection［J］. J Allergy Clin Immunol Pract, 2020,8（1）:91⁃101. doi: 10.1016/j.jaip.2019.06.044.
［48］	Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double⁃blind studies［J］. J Am Acad Dermatol, 2021,85（4）:863⁃872. doi: 10.1016/j.jaad.2021. 04.085.
［49］	Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis［J］. Expert Rev Clin Pharmacol, 2018,11（5）:467⁃474. doi: 10.1080/17512433.2018.1449642.
［50］	Silverberg JI, Guttman⁃Yassky E, Gadkari A, et al. Real⁃world persistence with dupilumab among adults with atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2021,126（1）:40⁃45. doi: 10.1016/j.anai.2020.07.026.
［51］	Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real⁃life study［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:958⁃964. doi: 10.1111/jdv.17094.
［52］	贾元源, 毛秋雨, 杨婧怡, 等. 度普利尤单抗治疗中重度老年特应性皮炎临床疗效观察［J］. 中华皮肤科杂志, 2023,56（2）:125⁃129. doi: 10.35541/cjd.20220516.
［53］	中华医学会皮肤性病学分会特应性皮炎研究中心, 中华医学会皮肤性病学分会儿童学组. 度普利尤单抗治疗特应性皮炎专家共识［J］.中华皮肤科杂志, 2022,55（6）:465⁃470. doi: 10.35541/cjd.20210885
［54］	Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: a systematic review［J］. J Am Acad Dermatol, 2021,84（5）:1339⁃1347. doi: 10.1016/j.jaad.2021.01.012.
［55］	Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review［J］. J Am Acad Dermatol, 2022,86（3）:708⁃709. doi: 10.1016/j.jaad.2021. 05.013.
［56］	Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate⁃to⁃severe uncontrolled asthma［J］. N Engl J Med, 2018,378（26）:2486⁃2496. doi: 10.1056/NEJMoa1804092.
［57］	Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema: part I ⁃ systemic therapy［J］. J Eur Acad Dermatol Venereol, 2022,36（9）:1409⁃1431. doi: 10. 1111/jdv.18345.
［58］	Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis［J］. J Allergy Clin Immunol, 2021,148（4）:927⁃940. doi: 10.1016/j.jaci.2021.08.009.
［59］	He H, Guttman⁃Yassky E. JAK Inhibitors for atopic dermatitis: an update［J］. Am J Clin Dermatol, 2019,20（2）:181⁃192. doi: 10.1007/s40257⁃018⁃0413⁃2.
［60］	Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018［J］. J Dermatol, 2019,46（12）:1053⁃1101. doi: 10.1111/1346⁃8138.15090.
［61］	Simon D, Bieber T. Systemic therapy for atopic dermatitis［J］. Allergy, 2014,69（1）:46⁃55. doi: 10.1111/all.12339.
［62］	中国医师协会皮肤科医师分会自身免疫病专业委员会. 环孢素治疗免疫相关性皮肤病专家建议［J］. 中华皮肤科杂志, 2022,55（6）:471⁃479. doi: 10.35541/cjd.20210434.
［63］	Wallace DV. Treatment options for moderate to severe atopic dermatitis［J］. Allergy Asthma Proc, 2022,43（6）:474⁃493. doi: 10.2500/aap.2022.43.220076.
［64］	Fulop T, Larbi A, Kotb R, et al. Aging, immunity, and cancer［J］. Discov Med, 2011,11（61）:537⁃550.
［65］	颜克香. 甲氨蝶呤在皮肤科的临床应用及注意事项［J］. 皮肤科学通报, 2021,38（4）:320⁃326.
［66］	Purvis D, Lee M, Agnew K, et al. Long⁃term effect of methotrexate for childhood atopic dermatitis［J］. J Paediatr Child Health, 2019,55（12）:1487⁃1491. doi: 10.1111/jpc.14478.
［67］	Du⁃Thanh A, Merlet S, Maillard H, et al. Combined treatment with low⁃dose methotrexate and initial short⁃term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study［J］. Br J Dermatol, 2011,165（6）:1337⁃1343. doi: 10.1111/j.1365⁃2133.2011.10531.x.
［68］	Gori N, Chiricozzi A, Malvaso D, et al. Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy［J］. Dermatology, 2021,237（4）:535⁃541. doi: 10.1159/000512890.
［69］	Gerbens L, Hamann S, Brouwer M, et al. Methotrexate and azathioprine for severe atopic dermatitis: a 5⁃year follow⁃up study of a randomized controlled trial［J］. Br J Dermatol, 2018,178（6）:1288⁃1296. doi: 10.1111/bjd.16240.
［70］	Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta⁃analysis［J］. JAMA Dermatol, 2020,156（6）:659⁃667. doi: 10.1001/jamadermatol.2020. 0796.
［71］	Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy［J］. Gastroenterology, 2015,148（1）:215⁃219; quiz e16⁃17. doi: 10.1053/j.gastro.2014.10.039.
［72］	Mashiah J, Karady T, Fliss⁃Isakov N, et al. Clinical efficacy of fecal microbial transplantation treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. Immun Inflamm Dis, 2022,10（3）:e570. doi: 10.1002/iid3.570.
［73］	Jiang X, Liu Z, Ma Y, et al. Fecal microbiota transplantation affects the recovery of AD⁃skin lesions and enhances gut microbiota homeostasis［J］. Int Immunopharmacol, 2023,118:110005. doi: 10.1016/j.intimp.2023.110005.
［74］	Huang R, Ning H, Shen M, et al. Probiotics for the treatment of atopic dermatitis in children: a systematic review and meta⁃analysis of randomized controlled trials［J］. Front Cell Infect Microbiol, 2017,7:392. doi: 10.3389/fcimb.2017.00392.
［75］	Mittal A, Agarwal C, Balai M, et al. Gabapentin and pregabalin in dermatology［J］. Indian J Dermatol Venereol Leprol, 2018,84（5）:634⁃640. doi: 10.4103/ijdvl.IJDVL_480_17.
［76］	中国医师协会皮肤科医师分会过敏性疾病专业委员会, 中华医学会皮肤性病学分会特应性皮炎研究中心, 中国医疗保健国际交流促进会皮肤科分会. 特应性皮炎瘙痒管理专家共识［J］. 中华皮肤科杂志, 2021,54（5）:391⁃396. doi: 10.35541/cjd.20210056.
［77］	Zirwas MJ. Dramatic response to chloroquine and mirtazapine for recalcitrant atopic dermatitis［J］. Dermatitis, 2006,17（4）:208⁃210. doi: 10.2310/6620.2006.06013.
［78］	Sun PY, Li HG, Xu QY, et al. Lidocaine alleviates inflammation and pruritus in atopic dermatitis by blocking different population of sensory neurons［J］. Br J Pharmacol, 2023,180（10）:1339⁃1361. doi: 10.1111/bph.16012.
［79］	Kemény L, Varga E, Novak Z. Advances in phototherapy for psoriasis and atopic dermatitis［J］. Expert Rev Clin Immunol, 2019,15（11）:1205⁃1214. doi: 10.1080/1744666X.2020.1672537.
［80］	Liu L, Luo Y, Zhou M, et al. Tripterygium agents for the treatment of atopic eczema: a Bayesian analysis of randomized controlled trials［J］. Phytomedicine, 2019,59:152914. doi: 10. 1016/j.phymed.2019.152914.
［81］	Tan HY, Lenon GB, Zhang AL, et al. Efficacy of acupuncture in the management of atopic dermatitis: a systematic review［J］. Clin Exp Dermatol, 2015,40（7）:711⁃716. doi: 10.1111/ced.12732.

[1]	Wang Yuqian, Qiao Jianjun, Fang Hong. Comparison of the latest Chinese and international guidelines/consensus on diagnosis and treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 885-888.
[2]	Chen Yaolong, Liu Hui, Yao Zhirong, Gao Xinghua. Strategies and suggestions for improving the quality of guidelines and consensus in the field of dermatology [J]. Chinese Journal of Dermatology, 2023, 56(9): 805-808.
[3]	Yuan Xingang, Ni Sili, Zhang Jian, Luo Xiaoyan, Wang Hua. Improving diagnosis and treatment of melanocytic nevi in children: an urgent need [J]. Chinese Journal of Dermatology, 2023, 56(8): 782-786.
[4]	China Dermatologist Association. Guidance on application of moisturizers and emollients: an expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(8): 711-717.
[5]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[6]	Mi Shuhong, Yu Yanqin, Hao Jinqi, Li Wei, Zhang Yang, Jia Ximei, Huang Yuxian, Sun Huaiyu, Shi Jihai. Analysis of imaging characteristics of papulopustular rosacea by high-frequency ultrasound combined with color Doppler flow imaging [J]. Chinese Journal of Dermatology, 2023, 56(6): 540-544.
[7]	Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.
[8]	Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566.
[9]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[10]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.
[11]	Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on treat-to-target in chronic spontaneous urticaria （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 489-495.
[12]	Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.
[13]	Hu Qingjie, Zhou Min, Yao Xu. Analysis of clinical characteristics of 36 patients with pyoderma gangrenosum and comparison between the PARACELSUS score and Delphi criteria for their diagnosis [J]. Chinese Journal of Dermatology, 2023, 56(5): 410-414.
[14]	Committee on Sexually Transmitted Diseases, China Dermatologist Association. Expert consensus on clinical management of serofast state in syphilis （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 383-388.
[15]	Wang Min, He Pingxiu, Cheng Lifang, Hong Kechun, Ai Yong. A case of meningothelial hamartoma of the scalp [J]. Chinese Journal of Dermatology, 2023, 56(5): 449-450.

Expert consensus on diagnosis and treatment of atopic dermatitis in the elderly （2023）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［81］

Related Articles 15

Metrics

Comments

Recommended 10